Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
Bireociclib plus fulvestrant nearly doubled progression-free survival compared with fulvestrant alone in HR-positive, HER2-negative advanced breast cancer. Benefits were consistent across high-risk ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA® (pembrolizumab) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results